NEW YORK (Reuters) -Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans ...

Evernorth — the Cigna division that oversees the Express ... monthly copays for two popular weight-loss drugs, Wegovy and Zepbound, at $200. The impact on the employers' spending is unclear ...

Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

Evernorth, the health services division of The Cigna Group, announced the benefit that will make popular weight loss medications Wegovy and Zepbound more available to patients. Through direct ...

Only half of health insurer Cigna's clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company's pharmacy benefits unit Evernorth ...

Cigna's Evernorth is rolling out a new pharmacy ... arm it negotiated directly with the manufacturers for Wegovy and Zepbound—Novo Nordisk and Eli Lilly, respectively—to cap patients' monthly ...

Cigna Group’s drug benefit unit is offering ... patients would pay less than the cash price for Eli Lilly & Co.’s Zepbound or Novo Nordisk A/S’s Wegovy, but typically more than the normal ...

Cigna is building on client demand for tools ... such as Eli Lilly’s Zepbound, could be more expensive. “We don’t necessarily see formulary placement or choosing one drug over another ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on ...

The GLP-1 drugs are currently only covered by half of The Cigna Group (NYSE:CI)'s clients. Customers who now provide coverage could save as much as 20%. The agreement comes after Lilly's Zepbound ...